23andMe Investor Presentation Deck

NEED: Our Unique Approach to De-risk Development: Leveraging Pleiotropy to Characterize Novel Cancer Targets 23andMe "IO Signature" Type 1 diabetes thyroid diseases celiac RA psoriasis SCC BCC Melanoma Variant 1 Variant 2 CTLA4 gene increased risk signed log(p) 10 5 -5 -10 decreased risk 23ME-00610 Lead Asset (currently in Ph2a*) CD200R1 Basal cell carcinoma Hypothyroidism Hashimoto's DOK2 Basal cell carcinoma Mosquito bite itch/size Eczema Any asthma Any allergy Juvenile asthma Any animal allergy *Currently in Phase 2a portion of Phase 1/2a Cancer Immune 10 5 -5 -10 -Log(P value) Investigator-assessed irAEs Genomic data successfully predicted '610 AE Profile 1400 mg- 600 mg 200 mg- 60 mg 20 mg 6 mg 2 mg 8 5 10 15 20 % of Phase 1 Participants Hypothyrodism Pruritus Rash/Rash maculo-papular Copyright © 2024 23andMe, Inc. 25 23andMe 30 14

View entire presentation